Annals of medicine and surgery (2012) · 2022
Inotropic support in cardiogenic shock: who leads the battle, milrinone or dobutamine?
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lozada Martinez Ivan David, Bayona-Gamboa Andrea Juliana, Meza-Fandiño Duvier Fabián, Paz-Echeverry Omar Andrés, Ávila-Bonilla Ángela María, Paz-Echeverry Mario Javier, Pineda-Trujillo Frank Jaider, Rodríguez-García Gina Paola, Covaleda-Vargas Jaime Enrique, Narvaez-Rojas Alexis Rafael
Аннотация
Cardiovascular diseases remain the leading cause of death globally, with acute myocardial infarction being one of the most frequent. One of the complications that can occur after a myocardial infarction is cardiogenic shock. At present, the evidence on the use of inotropic agents for the management of this complication is scarce, and only a few trials have evaluated the efficacy-adverse effects relationship of some agents. Milrinone and Dobutamine are some of the most frequently mentioned drugs that have been studied recently. However, there are still no data that affirm with certainty the supremacy of one over the other. The aim of this review is to synthesize evidence on basic and practical aspects of these agents, allowing us to conclude which might be more useful in current clinical practice, based on the emerging literature.